world
health
organis
receiv
first
report
oseltamivirresist
influenza
viru
juli
sequenc
analysi
reveal
resist
associ
histidin
tyrosin
substitut
viral
neuraminidas
posit
sinc
discoveri
total
oseltamivirresist
influenza
mutant
case
report
global
influenza
surveil
network
gisn
case
immunocompromis
patient
receiv
prolong
oseltamivir
treatment
associ
oseltamivir
treatment
sever
case
also
associ
chemoprophylaxi
mmwr
cdc
also
case
found
individu
receiv
treatment
chen
et
al
despit
increas
number
case
two
report
person
person
transmiss
resist
viru
gulland
one
report
commun
cluster
oseltamivir
resist
case
le
et
al
howev
evid
ongo
circul
viru
commun
furthermor
resist
strain
shown
caus
alter
sever
infect
abl
detect
rapidli
emerg
resist
viru
import
allow
clinician
chang
rapidli
patient
treatment
effect
drug
case
bar
one
remain
sensit
zanamivir
inform
also
inform
infect
control
procedur
public
health
surveil
numer
methodolog
avail
detect
antivir
drug
resist
influenza
virus
phenotyp
assay
gold
standard
oseltamivir
resist
test
zambon
hayden
howev
method
time
consum
expens
avail
specialist
centr
newer
method
pyrosequenc
rapid
sensit
detect
laboratori
equip
machin
cdc
group
rotterdam
develop
recent
realtim
pcr
base
method
detect
person
commun
schutten
method
shown
sensit
rapid
unlik
aforement
method
use
chemistri
avail
diagnost
laboratori
incorpor
resist
type
assay
establish
duplex
assay
detect
influenza
type
simultan
posit
describ
new
assay
allow
rapid
diagnosi
type
resist
test
respiratori
sampl
real
time
univers
influenza
influenza
assay
develop
inhous
publish
previous
univers
influenza
assay
wide
use
assay
target
matrix
region
viru
particip
variou
extern
qualiti
assess
eqa
scheme
shown
assay
detect
influenza
virus
human
anim
high
sensit
assay
specif
influenza
resist
assay
develop
group
rotterdam
suppli
person
commun
schutten
allel
discrimin
assay
design
distinguish
cytosin
oseltamivir
sensit
thymidin
oseltamivir
resist
mutat
nucleotid
posit
gene
influenza
give
rise
antivir
resist
probe
resist
assay
modifi
develop
assay
ad
two
nucleotid
tt
end
later
date
publish
van
der
vri
et
al
note
use
adapt
probe
probe
paper
also
use
studi
well
valid
probe
use
laboratori
primer
probe
concentr
assay
optimis
individu
use
inhous
protocol
gunson
et
al
gunson
et
al
resist
assay
use
primer
optimis
concentr
probe
l
reaction
volum
univers
influenza
duplex
use
primer
optimis
concentr
probe
l
reaction
volum
triplex
use
primer
optimis
concentr
univers
influenza
probe
probe
l
reaction
volum
primer
probe
shown
tabl
assay
onestep
rtrtpcr
perform
rna
extract
platinum
onestep
qrtpcr
kit
invitrogen
abi
prism
sd
realtim
platform
appli
biosystem
follow
thermal
profil
use
singl
cycl
revers
transcript
min
c
min
c
revers
transcriptas
inactiv
dna
polymeras
activ
follow
amplif
cycl
c
c
annealingextens
step
threshold
set
manual
analysi
specif
triplex
assay
assess
use
panel
panel
contain
season
influenza
avian
virus
panel
also
contain
influenza
pool
contain
follow
commonli
encount
respiratori
pathogen
also
test
influenza
b
adenoviru
coronaviru
parainfluenza
rhinoviru
respiratori
syncyti
viru
human
metapneumoviru
mycoplasma
pneumonia
compon
present
pool
present
ct
valu
endpoint
detect
limit
univers
influenza
compon
triplex
directli
compar
publish
duplex
use
dilut
seri
influenza
clinic
sampl
clinic
sampl
contain
season
virus
dilut
test
duplic
carri
ensur
addit
assay
univers
influenza
duplex
result
reduct
endpoint
detect
limit
univers
influenza
compon
endpoint
detect
limit
compon
triplex
compar
directli
singl
assay
use
dilut
seri
influenza
posit
clinic
sampl
dilut
test
duplic
carri
ensur
addit
assay
univers
influenza
duplex
result
reduct
endpoint
detect
limit
compon
new
triplex
assay
also
directli
compar
univers
influenza
assess
interassay
variabl
reproducibilitylongterm
precis
posit
extract
run
control
flua
monitor
pcr
run
assess
intraassay
variabl
repeatabilityshortterm
precis
posit
extract
run
control
flua
test
well
pcr
run
final
abil
triplex
assay
detect
minor
popul
oseltamivir
resist
influenza
viru
sampl
contain
mixtur
resist
sensit
virus
assess
similar
concentr
wildtyp
influenza
rna
control
mix
dilut
posit
rna
wildtyp
wt
rna
dilut
resist
viru
wildtyp
viru
repres
decreas
popul
resist
rna
mix
strain
sampl
allow
predict
approxim
level
minor
popul
resist
rna
could
detect
clinic
sampl
extract
qiagen
mdx
use
qiaamp
viral
rna
kit
qiagen
crawley
uk
accord
manufactur
instruct
triplex
evalu
use
influenza
qualiti
control
panel
univers
influenza
compon
triplex
assay
detect
success
sampl
contain
influenza
subtyp
tabl
compon
assay
detect
sampl
posit
pool
respiratori
pathogen
test
use
triplex
crossreact
observ
endpoint
detect
limit
univers
influenza
compon
triplex
assay
comparison
duplex
assay
assess
use
serial
dilut
clinic
sampl
contain
influenza
season
virus
tabl
test
dilut
seri
influenza
sampl
influenza
compon
duplex
detect
dilut
occas
wherea
influenza
compon
triplex
assay
detect
dilut
occas
compon
duplex
triplex
detect
dilut
compon
triplex
detect
sampl
dilut
seri
posit
tabl
test
dilut
seri
season
clinic
sampl
influenza
compon
duplex
assay
detect
dilut
dilut
seri
wherea
influenza
compon
triplex
detect
dilut
occas
influenza
compon
duplex
triplex
detect
dilut
dilut
seri
compon
triplex
detect
sampl
dilut
seri
posit
tabl
final
endpoint
detect
experi
compar
compon
triplex
assay
singl
assay
test
serial
dilut
influenza
clinic
sampl
known
contain
mutat
singl
assay
detect
wherea
compon
triplex
detect
note
compon
triplex
similar
endpoint
detect
resist
rna
influenza
tabl
triplex
compar
duplex
assay
clinic
sampl
taken
patient
clinic
diagnosi
influenza
total
posit
assay
discrep
these
discrep
posit
duplex
neg
triplex
influenza
posit
posit
posit
triplex
neg
duplex
influenza
posit
posit
sampl
discrep
high
threshold
cycl
ct
valu
rang
endpoint
detect
limit
assay
see
tabl
interassay
variabl
assess
monitor
posit
run
control
pcr
run
intraassay
variabl
test
posit
control
well
one
pcr
run
tabl
result
suggest
littl
interassay
variabl
ct
compon
similar
differ
run
low
standard
deviat
sd
coeffici
variat
cov
valu
result
also
suggest
intraassay
variabl
assay
also
good
compon
littl
variat
observ
posit
control
repeatedli
test
note
control
use
weaker
compon
assay
nearer
endpoint
detect
limit
see
tabl
test
like
caus
slightli
higher
sd
cov
valu
overal
result
suggest
triplex
assay
precis
robust
final
abil
triplex
assay
detect
minor
popul
assess
test
dilut
rna
dilut
wt
rna
result
suggest
reliabl
detect
dilut
tabl
repres
minor
popul
present
studi
multiplex
assay
detect
influenza
simultan
type
influenza
highlight
whether
viru
contain
mutat
develop
ad
discrimin
assay
publish
duplex
assay
shown
effect
perform
individu
compon
shown
use
sever
dilut
seri
number
eqa
panel
prospect
clinic
sampl
taken
patient
clinic
diagnos
multiplex
method
detriment
effect
ct
valu
compon
slightli
improv
perform
compon
triplex
multiplex
also
precis
robust
shown
assess
interassay
intraassay
variabl
individu
compon
assay
multiplex
differ
test
compon
offer
sever
advantag
futur
outbreak
viru
mention
previou
public
multiplex
univers
assay
type
assay
allow
laboratori
screen
respiratori
sampl
influenza
viru
rapid
cost
effect
format
ensur
type
method
season
avian
virus
use
smaller
subset
sampl
incorpor
resist
assay
achiev
littl
extra
cost
gunson
et
al
sinc
virolog
laboratori
alreadi
offer
molecular
servic
influenza
assay
could
easili
implement
area
therefor
increas
local
access
resist
test
access
local
servic
offer
sever
clinic
advantag
current
system
reli
upon
sampl
refer
specialist
centr
exampl
assay
allow
detect
resist
viru
patient
monitor
presenc
influenza
consequ
clinician
chang
effect
treatment
much
earlier
stage
current
achiev
mention
number
report
resist
viru
found
patient
histori
receiv
oseltamivir
result
assay
would
also
prove
use
surveil
oseltamivir
resist
influenza
strain
commun
lackenbi
et
al
season
influenza
season
oseltamivirresist
strain
becam
domin
strain
circul
commun
therefor
possibl
could
happen
pandem
strain
next
influenza
season
harvala
et
al
import
note
assay
detect
mutat
influenza
viru
detect
mutat
associ
resist
consequ
resist
still
suspect
influenza
posit
patient
test
neg
oseltamivir
resist
mutat
consid
sampl
sent
specialist
test
collin
et
al
